<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02178579</url>
  </required_header>
  <id_info>
    <org_study_id>140404</org_study_id>
    <nct_id>NCT02178579</nct_id>
  </id_info>
  <brief_title>Prospective Observation of Cardiac Safety With Proteasome Inhibition</brief_title>
  <acronym>PROTECT</acronym>
  <official_title>Prospective Observation of Cardiac Safety With Proteasome Inhibition</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to better define and understand potential cardiac toxicities of&#xD;
      proteasome inhibitors and to understand optimal management strategies to treat and prevent&#xD;
      cardiovascular events.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cancer treatments, using proteasome inhibitors, have the potential in induce cardiac&#xD;
      toxicities including heart failure (HF), hypertension, arrhythmias and ischemic heart&#xD;
      disease. While the presence of cardiac events may be a class effect of proteasome inhibitors&#xD;
      (PI), the effect may be more profound with the irreversible inhibition of carfilzomib&#xD;
      compared with reversible inhibition with bortezomib. Data available from currently published&#xD;
      clinical trials may be inadequate to fully understand the incidence and severity of cardiac&#xD;
      injury in patients treated with proteasome inhibitors because the trials were not designed to&#xD;
      fully assess cardiac events. The purpose of this study is to better define and understand&#xD;
      potential cardiac toxicity and begin to understand optimal management strategies.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 2014</start_date>
  <completion_date type="Actual">July 15, 2019</completion_date>
  <primary_completion_date type="Actual">July 15, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of cardiac events of patients receiving PIs for MM.</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">95</enrollment>
  <condition>Heart Failure</condition>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Multiple Myeloma (MM) treatment with bortezomib</arm_group_label>
    <description>No intervention planned.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple Myeloma (MM) treatment with carfilzomib</arm_group_label>
    <description>No intervention planned.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood sample banked for future research.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Multiple Myeloma patients being treated with bortezomib or carfilzomib, per oncology&#xD;
        physician decision.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Relapsed multiple myeloma at any time-point in treatment course and planning to start&#xD;
             a proteasome inhibitor-based therapy as part of standard care&#xD;
&#xD;
          -  Received at least one prior line of therapy for multiple myeloma (induction therapy&#xD;
             followed by stem cell transplant and consolidation/maintenance therapy will be&#xD;
             considered as one line of therapy)&#xD;
&#xD;
          -  Males and females ≥ 18 years of age&#xD;
&#xD;
          -  Able to provide written informed consent in accordance with federal, local, and&#xD;
             institutional guidelines&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and&#xD;
             skin changes)&#xD;
&#xD;
          -  Known or suspected AL amyloidosis, secondary amyloidosis or cardiac amyloidosis&#xD;
&#xD;
          -  Plasma cell leukemia (&gt; 2.0 × 109/L circulating plasma cells by standard differential)&#xD;
&#xD;
          -  Waldenström Macroglobulinemia&#xD;
&#xD;
          -  Myelodysplastic syndrome&#xD;
&#xD;
          -  History of MI within the last 3 months&#xD;
&#xD;
          -  Symptomatic unstable cardiac arrhythmia requiring treatment in the past 3 months&#xD;
&#xD;
          -  Class 3 or 4 New York Heart Association Heart Failure in the past 3 months&#xD;
&#xD;
          -  Any other clinically significant medical disease or condition that, in the&#xD;
             investigator's opinion, may interfere with protocol adherence or a subject's ability&#xD;
             to give informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert F Cornell, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Pennsylvania/Smilow Center for Translational Research</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104-5159</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>June 26, 2014</study_first_submitted>
  <study_first_submitted_qc>June 26, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 1, 2014</study_first_posted>
  <last_update_submitted>September 10, 2020</last_update_submitted>
  <last_update_submitted_qc>September 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Heart Failure</keyword>
  <keyword>Cardiac Toxicity</keyword>
  <keyword>Multiple Myeloma</keyword>
  <keyword>Bortezomib</keyword>
  <keyword>Carfilzomib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>There are no plans to share individual participant data.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

